APA (7th ed.) Citation

K, M., T, Y., T, K., S, K., R, M., T, T., . . . T, K. (2025). Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab. International journal of clinical oncology, 30(11), 2335. https://doi.org/10.1007/s10147-025-02878-z

Chicago Style (17th ed.) Citation

K, Mori, et al. "Predictors of Early Progressive Disease and Antitumor Effects by Metastatic Site in Renal Cell Carcinoma Treated with Ipilimumab Plus Nivolumab." International Journal of Clinical Oncology 30, no. 11 (2025): 2335. https://doi.org/10.1007/s10147-025-02878-z.

MLA (9th ed.) Citation

K, Mori, et al. "Predictors of Early Progressive Disease and Antitumor Effects by Metastatic Site in Renal Cell Carcinoma Treated with Ipilimumab Plus Nivolumab." International Journal of Clinical Oncology, vol. 30, no. 11, 2025, p. 2335, https://doi.org/10.1007/s10147-025-02878-z.